Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) Director Matthew Shawn Morris sold 1,017 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $24.96, for a total transaction of $25,384.32. Following the sale, the director directly owned 68,188 shares of the company's stock, valued at approximately $1,701,972.48. The trade was a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Matthew Shawn Morris also recently made the following trade(s):
- On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The shares were sold at an average price of $24.99, for a total transaction of $427,229.04.
- On Thursday, February 26th, Matthew Shawn Morris sold 7,788 shares of Privia Health Group stock. The shares were sold at an average price of $24.99, for a total transaction of $194,622.12.
- On Friday, February 27th, Matthew Shawn Morris sold 16,550 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $413,750.00.
Privia Health Group Stock Performance
PRVA stock opened at $24.29 on Wednesday. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of 142.88, a PEG ratio of 1.51 and a beta of 0.96. The firm has a 50-day simple moving average of $22.64 and a two-hundred day simple moving average of $23.36. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51.
Privia Health Group (NASDAQ:PRVA - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.04 by $0.21. The business had revenue of $541.17 million during the quarter, compared to analyst estimates of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The company's quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 earnings per share. As a group, equities analysts predict that Privia Health Group, Inc. will post 0.37 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in PRVA. Wealth Alliance LLC lifted its holdings in Privia Health Group by 4.4% in the third quarter. Wealth Alliance LLC now owns 11,979 shares of the company's stock valued at $298,000 after acquiring an additional 508 shares during the period. Arizona State Retirement System lifted its holdings in Privia Health Group by 1.9% in the third quarter. Arizona State Retirement System now owns 28,835 shares of the company's stock valued at $718,000 after acquiring an additional 524 shares during the period. Illinois Municipal Retirement Fund lifted its holdings in Privia Health Group by 1.1% in the third quarter. Illinois Municipal Retirement Fund now owns 55,501 shares of the company's stock valued at $1,382,000 after acquiring an additional 585 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Privia Health Group by 9.6% in the third quarter. PNC Financial Services Group Inc. now owns 7,731 shares of the company's stock valued at $193,000 after acquiring an additional 675 shares during the period. Finally, Truist Financial Corp lifted its holdings in Privia Health Group by 4.6% in the third quarter. Truist Financial Corp now owns 17,634 shares of the company's stock valued at $439,000 after acquiring an additional 783 shares during the period. Hedge funds and other institutional investors own 94.48% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Privia Health Group in a report on Friday, January 9th. They set an "outperform" rating and a $31.00 price objective on the stock. Truist Financial upped their price objective on shares of Privia Health Group from $31.00 to $33.00 and gave the company a "buy" rating in a report on Monday, March 2nd. Barclays upped their price objective on shares of Privia Health Group from $23.00 to $25.00 and gave the company an "equal weight" rating in a report on Wednesday, March 25th. Wolfe Research set a $31.00 price objective on shares of Privia Health Group in a report on Tuesday, January 6th. Finally, Jefferies Financial Group restated a "buy" rating and set a $32.00 price objective on shares of Privia Health Group in a report on Thursday, February 26th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $31.31.
Get Our Latest Stock Report on PRVA
Privia Health Group News Roundup
Here are the key news stories impacting Privia Health Group this week:
- Positive Sentiment: Recent operating momentum — Privia beat consensus in its prior quarter (reported 2/26: $0.25 EPS vs. $0.04 est; revenue $541.2M vs. $516.6M; revenue +17.4% YoY), which supports the view that the company can continue to grow revenue and expand services. MarketBeat PRVA profile
- Neutral Sentiment: Q1 earnings event — Privia is scheduled to report Q1 results on Thursday; previews point to investor focus on revenue growth, margin trends and FY guidance. The upcoming release is the main near-term catalyst. Privia to Release Earnings
- Neutral Sentiment: Analyst/preview coverage — Recent previews summarize expectations and items to watch heading into the print (revenue, patient volumes, cost structure). These previews set a framework for whether the stock reaction will be driven by beats, guidance, or execution detail. MSN Q1 preview
- Negative Sentiment: Insider selling — CFO David Mountcastle disclosed Rule 10b5-1 sales (7,179 shares on May 1 at ~$25.03 and 1,206 shares on May 4 at ~$25.00). While pre-arranged plans reduce governance concerns, these transactions can pressure sentiment in the short term. CFO Form 4
- Negative Sentiment: Director selling — Director Matthew Shawn Morris sold 17,096 shares (May 1, ~$24.99) and 1,017 shares (May 4, ~$24.96) under a 10b5-1 plan, a meaningful reduction in his holding. Again, the 10b5-1 context tempers governance concerns but may weigh on near-term sentiment. Director Form 4
About Privia Health Group
(
Get Free Report)
Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.
Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
